Search

everythinglearnresearchcommunity

for

Search:↓

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

5% minoxidil foam is effective and safe for hair regrowth in women with hair loss.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

The oral contraceptive with ethinyl estradiol and chlormadinone acetate is effective in treating moderate acne.

The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.

Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution are similarly effective and safe for female pattern hair loss.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

The new gel combining calcipotriene and betamethasone is effective and safe for treating scalp psoriasis.

Dutasteride is a safe and effective treatment for hair loss.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Clascoterone is a new, effective, and safe acne treatment without systemic side effects.

Topical finasteride is a safe and effective treatment for pattern hair loss with fewer side effects than oral finasteride.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.